Medicure Reports Financial Results for the Year Ended December 31, 2025 and Schedules April 27, 2026 Conference Call
Medicure reported fiscal 2025 total net revenue of $28.9 million, up from $21.9 million in the prior year, driven primarily by the integration of newly acquired pharmacies. However, core product AGGRASTAT sales declined to $5.7 million from $8.1 million, and the company swung to a net loss of $7.1 million, or $0.68 per share.
Key figures
- Revenue
- $28.9 million
- Net loss
- $7.1 million
- Adjusted ebitda
- negative $1.5 million
- Aggrastat revenue
- $5.7 million
- Unrestricted cash
- $3.8 million
- Research and development
- $3.2 million
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.